Erratum: Elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein-Barr virus antibodies (PLoS ONE (2015) 10:9 (e0138753) DOI: 10.1371/journal.pone.0138753);Elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein-Barr virus antibodies

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Draborg, Anette H ^a   Lydolph, Magnus C ^a   Westergaard, Marie ^a   Larsen, Severin Olesen ^a   Nielsen, Christoffer T ^a,b   Duus, Karen ^a   Jacobsen, Søren ^b   Houen, Gunnar ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; EPSTEIN BARR VIRUS ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN FREE LIGHT CHAIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; COMPLEMENT; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; KIDNEY FAILURE; MALE; NEPHELOMETRY; QUANTITATIVE ANALYSIS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; EPSTEIN BARR VIRUS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, VIRAL; AUTOANTIBODIES; B-LYMPHOCYTES; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COMPLEMENT SYSTEM PROTEINS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84946924410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148151     Document Type: Erratum

References (51)

1. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39: 257-268. S0049-0172 (08)00197-2 [pii]; PMID: 19136143
2. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM (2007) Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 56: 2092-2094. doi: 10.1002/art.22641 PMID: 17530651
3. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358: 929-939. 358/9/929 [pii]; doi: 10.1056/NEJMra071297 PMID: 18305268
4. Smith PP, Gordon C (2010) Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 10: 43-45. S1568-9972(10)00184-9 [pii]; doi: 10.1016/j.autrev.2010.08.016 PMID: 20850569
5. Dall'era M, Chakravarty EF (2011) Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep 13: 308-316. doi: 10.1007/s11926-011-0186-6 PMID: 21584692
6. Namjou B, Kilpatrick J, Harley JB (2007) Genetics of clinical expression in SLE. Autoimmunity 40: 602-612. 788414977 [pii]; doi: 10.1080/08916930701510962 PMID: 18075794
7. von Muhlen CA, Tan EM (1995) Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24: 323-358. S0049-0172(95)80004-2 [pii]. PMID: 7604300
8. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
9. Sakane T, Suzuki N, Takada S, Ueda Y, Murakawa Y, Tsuchida T et al. (1988) B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 31: 80-87. PMID: 3257876
10. Fauci AS, Moutsopoulos HM (1981) Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum 24: 577-583. PMID: 6971105
11. Nakano T, Matsui M, Inoue I, Awata T, Katayama S, Murakoshi T (2011) Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta 412: 843-849. S0009-8981(11)00136-7 [pii]; doi: 10.1016/j.cca.2011.03.007 PMID: 21396928
12. Hopper JE, SequeiraW, Martellotto J, Papagiannes E, Perna L, Skosey JL (1989) Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin. J Clin Immunol 9: 338-350. PMID: 2504765
13. Hopper JE, Golbus J, Meyer C, Ferrer GA (2000) Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 20: 123-137. PMID: 10821464
14. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A et al. (2011) Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken) 63: 891-898. doi: 10.1002/acr.20446
15. Chiche L, Cournac JM, Mancini J, Bardin N, Thomas G, Jean R et al. (2011) Normalization of serumfree light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin Rheumatol 30: 685-689. doi: 10.1007/s10067-010-1674-1 PMID: 21221683
16. Jolly M, Francis S, Aggarwal R, Mikolaitis R, Niewold T, Chubinskaya S et al. (2014) Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus 23: 881-888. 0961203314530793 [pii]; doi: 10.1177/0961203314530793 PMID: 24786785
17. Mastroianni-Kirsztajn G, Nishida SK, Pereira AB (2008) Are urinary levels of free light chains of immunoglobulins useful markers for differentiating between systemic lupus erythematosus and infection? Nephron Clin Pract 110: c258-c263. 000167874 [pii]; doi: 10.1159/000167874 PMID: 18974658
18. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA (2005) EBV and systemic lupus erythematosus: a new perspective. J Immunol 174: 6599-6607. 174/11/6599 [pii]. PMID: 15905498
19. Kang I, Quan T, Nolasco H, Park SH, Hong MS, Crouch J et al. (2004) Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 172: 1287-1294. PMID: 14707107
20. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH et al. (2004) Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 6: R295-R302. [pii]. PMID: 15225364
21. Yu SF, Wu HC, Tsai WC, Yen JH, Chiang W, Yuo CY et al. (2005) Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol 194: 115-120. doi: 10.1007/s00430-004-0230-5 PMID: 15378356
22. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA (2005) Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11: 85-89. nm1167 [pii]; doi: 10.1038/nm1167 PMID: 15619631
23. Auwaerter PG (1999) Infectious mononucleosis in middle age. JAMA 281: 454-459. jgh80003 [pii]. PMID: 9952206
24. Tattevin P, Le TY, Minjolle S, Person A, Chapplain JM, Arvieux C et al. (2006) Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. J Clin Microbiol 44: 1873-1874. 44/5/1873 [pii]; doi: 10.1128/JCM.44.5.1873-1874.2006 PMID: 16672427
25. Joseph AM, Babcock GJ, Thorley-Lawson DA (2000) Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74: 9964-9971. PMID: 11024124
26. Babcock GJ, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13: 497-506. S1074-7613(00)00049-2 [pii]. PMID: 11070168
27. Thorley-Lawson DA (2001) Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1: 75-82. PMID: 11905817
28. Schepers A, Pich D, HammerschmidtW(1996) Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology 220: 367-376. S0042-6822(96)90325-6 [pii]; doi: 10.1006/viro. 1996.0325 PMID: 8661388
29. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL et al. (2001) Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 44: 1122-1126. doi: 10.1002/1529-0131(200105)44:53.0.CO;2-D PMID: 11352244
30. Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, Lehmann PV, Anthony DD (2005) Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol 235: 29-38. S0008-8749(05)00104-8 [pii]; doi: 10.1016/j.cellimm.2005.06.010 PMID: 16181618
31. Tsokos GC, Magrath IT, Balow JE (1983) Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 131: 1797-1801. PMID: 6311898
32. Draborg AH, Jacobsen S, Westergaard M, Mortensen S, Larsen JL, Houen G et al. (2014) Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med 1: e000015. lupus-2014-000015 [pii]. PMID: 25396062
33. Draborg A, Jorgensen J, Muller H, Nielsen C, Jacobsen S, Iversen L et al. (2012) Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand J Rheumatol 41: 280-289. doi: 10.3109/03009742.2012.665944 PMID: 22646970
34. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB (1997) An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 100: 3019-3026. doi: 10.1172/JCI119856 PMID: 9399948
35. McClain MT, Poole BD, Bruner BF, Kaufman KM, Harley JB, James JA (2006) An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 54: 360-368. doi: 10.1002/art.21682 PMID: 16385527
36. Chen CJ, Lin KH, Lin SC, Tsai WC, Yen JH, Chang SJ et al. (2005) High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol 32: 44-47. 0315162X-32-44 [pii]. PMID: 15630723
37. Chen DY, Chen YM, Lan JL, Chen HH, Hsieh CW, Wey SJ et al. (2010) Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection? J Clin Virol 49: 290-295. S1386-6532(10)00357-4 [pii]; doi: 10.1016/j.jcv.2010.08.015 PMID: 20934910
38. Lu JJ, Chen DY, Hsieh CW, Lan JL, Lin FJ, Lin SH (2007) Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan. Lupus 16: 168-175. PMID: 17432101
39. Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St Clair EW et al. (2005) Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum 52: 1148-1159. doi: 10.1002/art.20997 PMID: 15818712
40. Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B et al. (2009) Infectious antibodies in systemic lupus erythematosus patients. Lupus 18: 1129-1135. 18/13/1129 [pii]; doi: 10.1177/0961203309345729 PMID: 19880558
41. Esen BA, Yilmaz G, Uzun S, Ozdamar M, Aksozek A, Kamali S et al. (2010) Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatol Int. doi: 10.1007/s00296-010-1573-4
42. Huggins ML, Todd I, Powell RJ (2005) Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 25: 183-187. doi: 10.1007/s00296-003-0420-2 PMID: 14666378
43. Stratta P, Canavese C, Ciccone G, Santi S, Quaglia M, Ghisetti V et al. (1999) Correlation between cytomegalovirus infection and Raynaud's phenomenon in lupus nephritis. Nephron 82: 145-154. 45391 [pii]. PMID: 10364707
44. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M et al. (2009) Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 1173: 658-663. NYAS4754 [pii]; doi: 10.1111/j.1749-6632.2009.04754.x PMID: 19758212
45. Csuka D, Simon D, Hobor R, Uray K, Prohaszka Z, Banlaki Z et al. (2013) Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. Clin Exp Immunol 171: 255-262. doi: 10.1111/cei.12022 PMID: 23379431
46. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR et al. (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-1444. PMID: 12194920
47. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M et al. (2007) Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 66: 23-27. ard.2006.052159 [pii]; doi: 10.1136/ard.2006.052159 PMID: 16569685
48. Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA (2010) Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol 229: 263-271. S0165-5728(10)00410-8 [pii]; doi: 10. 1016/j.jneuroim.2010.09.002 PMID: 20870296
49. Presslauer S, Milosavljevic D, Brucke T, Bayer P, HublW(2008) Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 255: 1508-1514. doi: 10.1007/s00415-008-0954-z PMID: 18685917
50. Hopper JE, Papagiannes E (1986) Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. Cell Immunol 101: 122-131. PMID: 3091263
51. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328-1337. doi: 10.1056/NEJMra032015; 350/13/1328 [pii]. PMID: 15044644